MBX Biosciences (MBX) Common Equity (2023 - 2026)

MBX Biosciences has disclosed Common Equity across 4 years of filings, most recently posting $437.8 million for Q1 2026.

• Common Equity for Q1 2026 came in at $437.8 million, up 85.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $437.8 million (up 85.95% YoY), and the FY2025 annual result was $369.2 million, up 43.42% from the prior year.
• Common Equity came in at $437.8 million for Q1 2026 at MBX Biosciences, up from $369.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $437.8 million in Q1 2026 to a low of -$97.9 million in Q2 2024.
• The 4-year median for Common Equity is $235.4 million (2025), against an average of $169.1 million.
• Across the five-year window, Common Equity jumped 518.66% in 2024 and surged 42.81% in 2025, its largest moves.
• MBX Biosciences' Common Equity stood at -$72.5 million in 2023, then jumped by 455.25% to $257.4 million in 2024, then surged by 43.42% to $369.2 million in 2025, then increased by 18.56% to $437.8 million in 2026.
• The last three Common Equity figures came in at $437.8 million (Q1 2026), $369.2 million (Q4 2025), and $387.5 million (Q3 2025), per Business Quant data.